Clinical Trial Update: First Patient Enrolled in Evommune’s Phase 2 Study of EVO756 in CIndU
The first patient has been enrolled in a Phase 2 trial of Evommune, Inc.’s EVO756 in adults with chronic inducible urticaria (CIndU). The trial aims to evaluate EVO756 in approximately 30 patients with symptomatic dermographism and cold urticaria in 15 study sites across the United States. EVO756 is a potent, highly selective small molecule antagonist of […]